Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Executive Summary
- Spectral Medical announced that the Phase 3 Tigris trial met its primary endpoint, showing a 95.3% posterior probability of benefit for 28‑day all‑cause mortality (adjusted OR 0.67) and >99% probability of benefit for 90‑day mortality (adjusted OR 0.54), translating to a 17.4% absolute reduction in mortality.
- The company pushed its FDA Premarket Approval (PMA) submission target to Q1 2026, citing ongoing interactive discussions on non‑clinical modules; the timing shift is not expected to affect commercialization plans.
- Financing: Vantive advanced a US$3 million Tranche B under a US$10 million promissory note (cumulative draw US$7 M); the company also received $2.5 M from warrant exercises and filed a final short‑form base shelf prospectus to enhance balance‑sheet flexibility.
Key Details
- Tigris Trial Results (Aug 12 2025):
- Primary endpoint met – 95.3% posterior probability of benefit for 28‑day mortality, adjusted odds ratio 0.67 (90% CI 0.39–1.08).
-
Key secondary endpoint – >99% posterior probability of benefit for 90‑day mortality, adjusted odds ratio 0.54 (90% CI 0.32–0.87); absolute mortality reduction 17.4%; NNT ≈ 8.1.
-
PMA Submission Timeline:
- Modular submission strategy; non‑clinical modules already under FDA review.
- Full PMA now targeted for Q1 2026 (previously Q4 2025).
-
Delay driven by incorporation of FDA feedback on non‑clinical items, human‑factors testing, and updated standards.
-
EDEN Study (Manuscript Sep 16 2025):
-
Observational data on 90 patients with endotoxic septic shock showed 28‑day mortality 57.1% vs 15.9% in other septic shock patients, informing potential labeling.
-
Commercialization Partner – Vantive:
-
Collaboration continues; Vantive to file a 510(k) for its PrisMax ICU platform (primary delivery system for PMX).
-
Financing Activity:
- Tranche B advance of US$3 M on Aug 22 2025 (cumulative US$7 M drawn vs total US$10 M facility).
- Warrant exercises generated net proceeds of $2.5 M during Q3 2025‑Nov 2 2025.
-
Filed final short‑form base shelf prospectus on Sep 29 2025 to provide optionality for future capital raises.
-
Financial Highlights (Q3 2025):
- Revenue up 34% YoY to $675 k (three months) and 26% YoY to $2.06 M (nine months).
- Operating loss widened to $30.3 M for the quarter (‑$0.11 per share) due primarily to non‑cash fair‑value adjustments of derivative liabilities.
-
Cash balance increased to $5.89 M at Sep 30 2025 from $2.99 M year‑end 2024.
-
Corporate Update Call:
- Scheduled for Wed, Dec 10 2025, 10:00 a.m. ET; CEO Chris Seto and CMO Dr. John Kellum to host.
Notable Quotes
“This was a transformative quarter for Spectral, highlighted by the positive topline results from Tigris,” – Chris Seto, CEO
“The positive Tigris results confirm a clinically meaningful survival benefit with PMX, validating our Bayesian approach and years of development.” – Dr. John Kellum, Chief Medical Officer